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Abstract 
Background: Several randomized phase III trials in neuroendocrine tumors (NETs) 
showed the clinical role of new targeted agents and their impact on tumor response and 
outcome of whose patients affected by advanced NET. In this study, we summarize the 
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available clinical data related to clinical efficacy of targeted therapies in the treatment of 
advanced NETs. 
Methods: A meta-analysis of randomized studies in accordance with the PRISMA 
guidelines was performed after searching the databases of PubMed, the Cochrane Library, 
and the ASCO University Meeting for relevant publications. 
Results: One thousand nine hundred and eight cases were included in the meta-analysis; 
among these, 1012 were in the experimental arm and 896 were in the control arm. The 
pooled analysis of the use of target agents in NETs revealed significantly increased of 
progression free survival compared to control group (hazard ratio=0.59, 95% CI:0.42-0.84; 
P=0.003). Subgroup analysis of patients according to tumour site showed a difference in 
favour of pancreatic neuroendocrine tumors. Moreover, targeted therapies improved the 
overall survival (hazard ratio=0.79, 95%CI: 0.63-0.98; P=0.03), and response rate (hazard 
ratio=3.33, 95% CI 2.02-5.49; P<0.00001) in all types of NETs. 
Conclusion: Our analysis supports the routine use of targeted agents for treatment of  
neuroendocrine tumors with particular regards to the pancreatic neuroendocrine tumors. 
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Introduction  
Neuroendocrine tumors (NET) arise from cells of the endocrine (hormonal) and nervous 
systems. NETs are considered a rare disease even their incidence appear to be increasing 
[1,2]. The prognosis of NETs may vary widely, depending on stage, grade or primary 
tumor site [3]. Surgical resection of the primary tumors usually offer the only change of a 
long curative treatment; however, only a low percentage of patients are candidate to 
surgery as more than 50% of patients with NET have regional or distant metastatic 
disease at diagnosis [3]. In advanced diseases, the therapeutic options may include: a 
close surveillance for slowly progressive tumours; a liver-directed treatments such as 
transarterial embolization; systemic treatment with cytotoxic chemotherapy or radionuclide. 
However, none of these approaches has been directly compared in randomised clinical 
trials [4]. 
In the armamentarium of systemic treatment, somatostatin analogues, such as octrotide 
and lanreotide, are currently indicated for the relief of symptoms in patients with 
functionally active NETs [5,6]. In addition, octreotide long-acting repeatable (LAR) has 
significantly prolonged time to tumor progression compared with placebo in patients with 
functionally active and inactive metastatic midgut NETs [7], supporting their use as a 
primary approach in the NET treatment. More recently, due to a better understanding of 
the biological mechanisms driving the growth of tumor cells with neuroendocrine 
phenotype has led to the development of targeted anti-cancer agents [8,9]. To date, two 
agents have been approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of patients with progressive, well-differentiated pancreatic NET: sunitinib (a 
vascular endothelial growth factor receptor-tyrosine kinase inhibitor) and everolimus (a 
mammalian target of rapamycin (mTOR). Three phase III trials demonstrated an improved 
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in progression-free survival (PFS) of both sunitinb and everolimus compared with placebo 
[10-12], supporting their role in clinical practice.   
The aim of this study is to analyse the available clinical data from randomized controlled 
trials (RCTs) looking for efficacy of target agents in patients with advanced NETs. 
 
Materials and methods 
Data retrieval strategies 
We conducted the meta-analysis of randomized studies in accordance with the PRISMA 
guidelines [13]. The databases of PubMed/MEDLINE, the Cochrane Library, and the 
American society of clinical oncology (ASCO) Meeting were searched for relevant 
publications using the following terms: „„Neuroendocrine tumour‟‟ or „„NET‟‟ or „„Carcinoid 
tumours‟‟ and “target therapy” or “sunitinib” or “everolimus” or “bevacizumab”. The 
publications that were available in these databases up to December 31, 2015, were 
analysed. The search was restricted to human studies, and the search criteria were limited 
to phase II or phase III trials. The computer search was supplemented with manual 
searches of the references listed in all of the retrieved review articles, including primary 
studies. When the results of a study were reported in subsequent interim analysis, only the 
most recent or complete and updated version was included in the analysis. 
Inclusion criteria  
The studies were identified according to the following inclusion criteria: 1) human 
participants with a NET; 2) a targeted agent therapy alone or in combination for 
experimental arm; 3) the presence of a control for comparison (placebo or not); 4) a 
primary outcome of response expressed as the hazard ratio (HR) for either PFS or overall 
survival (OS), as well as the response rate expressed as relative risk (RR). The following 
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exclusion criteria were used: 1) insufficient data were available to estimate the outcomes; 
2) animal studies; 3) the size of each arm was fewer than 10 participants; and 4) the 
presence of a single-arm study.  
Data extraction 
LZ and SV independently extracted the relevant data of each trials, including the name of 
the first author, country, publication year, characteristics of the enrolled patients, median 
follow-up and information about the study design (i.e., the type of blinding, type of control, 
and methods for randomization allocation), survival outcomes expressed as HRs for OS 
and PFS, and the number of patients who experienced a response rate with a grade 3-4 
adverse event. The arm with the targeted agent has been considered as the experimental. 
For the time-to-event variables (OS or PFS), HRs with the 95% confidence intervals 
(95%CIs) were calculated for each study. For the dichotomous variables (partial or 
complete response rate and toxicity) RRs with the 95% CIs were calculated for each study. 
Quality assessment and statistical analysis 
The methodological quality of each included study was assessed by two independent 
researchers (GA and PC). The study quality was assessed using the Jadad 5-item scale. 
The final score ranged from 0 to 5 [14]. Disagreements were evaluated by the kappa test, 
and consensus was achieved in discussion with the corresponding author (GR). 
Statistical analysis 
Statistical analyses were performed using Revman 5.3. The summary estimates were 
generated using a fixed-effects model (Mantel–Haenszel method) or a random-effects 
model (DerSimonian–Laird method) [15,16] depending on the absence or presence of 
heterogeneity. Statistical heterogeneity was assessed using the Q-test and the I2 statistic. 
I2 values of 25%, 50% and 75% were considered to indicate low, moderate and high 
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heterogeneity, respectively [17]. When P>0.1 in the Q-test and I2<50%, the fixed-effects 
model was used; otherwise, the random-effects model was used. Due to the small number 
of trials that were included, no publication bias was assessed. A sub-group analysis was 
performed to highlight any difference between studies with different tumour sites 
(pancreatic NETs versus other location). For all of the statistical analyses, a value of 
P<0.05 was regarded as statistically significant, and all of the tests were two-sided. 
Results 
Literature review, characteristics and quality of the included studies  
The search yielded 8454 potentially relevant articles. Of these, 7744 studies were 
excluded as duplicates. After viewing the titles and abstracts of the 710 remaining studies, 
the full texts of 21 studies were retrieved and seven studies [10-12,18-21] with 1012 cases 
in experimental arm and 896 cases in the control group were included in the meta-analysis 
according to the inclusion and exclusion criteria described in the materials and methods 
section (Fig. 1). One study was excluded because retracted by the authors [22]. Among 
these studies, 3 studies [10,12,18] investigated everolimus single agent as experimental 
arm, 3 studies sunitinib and bevacizumab respectively [11,19,20] and one study the 
combination of everolimus and bevacizumab [21]. Three studies enrolled patients with 
pancreatic NET [10,11,21,22] only. The patients‟ characteristics were obtained for all 
studies. The characteristics of the studies included in the meta-analysis are summarized in 
Table 1. There were 2 phase II studies [20,21] and 5 phase III studies [10-12,18,19]. All 
studies had a comparator: in 3 [10-12] the comparator was placebo, while in 1 was 
placebo plus octreotide LAR [18]; in 2 studies the comparator was pegylated (PEG)-
interferon alfa-2b and interferon respectively [19,20] and everolimus in on trial [21]. The 
median Jadad score was 5, showing a good quality of the included studies (Table 1). 
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Efficacy data 
Data about OS and PFS were reported in Table 2. With regard to OS, data were obtained 
from 4 studies [10-12,21]. The pooled analysis revealed that the new target therapies 
definitely improved the OS compared with control arm (0.79, 95%CI: 0.63-0.98; P=0.03, 
Figure 2). The analysis was performed using a fixed-effects model (I2=46%). In the 
experimental arm, a higher PFS has been observed respect control arm for all the included 
studies. All the studies reported HR for PFS, the pooled analysis revealed an improvement 
with new target therapies (HR=0.59, 95% CI:0.42-0.84; P=0.003 Figure 3). The random-
effects model was used for the analysis of the PFSs due to the presence of high 
heterogeneity (I2=87%) between the trials. In the subgroups analysis of the targeted 
agents in pancreatic and non-pancreatic NET, the results revealed the targeted therapies 
significantly improved the PFS to a greater extent in the pancreatic NET (HR=0.49 95%CI: 
0.29-0.83) than in non-pancreatic NET setting (HR=0.71 95%CI: 0.49-1.02) (Figure 3).  
Five studies reported the RR of the target agents in NET [11,19-21]. RR has been 
obtained in a total of 59/384 (15.3%) patients for the experimental group and in a total of 
17/383 (4.4%) patients in the control group. Using the Mantel–Haenszel method for 
combining trials, the pooled RR for achieving an objective response with targeted agents 
versus placebo or other therapies was 3.33 (95% CI 2.02–5.49; P<0.00001; I2=0%) 
(Figure 4). Regarding the toxicity, the data of the adverse events unfortunately were not 
homogeneously reported in the studies; therefore, an associated meta-analysis could not 
be performed.   
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Discussion 
Although the molecular background of sporadic NETs is unknown, several studies 
suggested that the abnormal PI3K-AKT-mTOR pathway signalling is implicated in their 
pathogenesis [23]. The mTOR protein is a serine-threonine kinase regulating cell growth, 
proliferation, metabolism, and angiogenesis and its autocrine activation, mediated mainly 
by the Insulin-like Growth Factor 1, has been associated with neuroendocrine tumour cell 
proliferation [24]. The crucial role of  mTOR pathway in NETs is also supported by the fact 
that NETs pathogenesis is frequently linked with familial cancer syndromes, such as 
neurofibromin 1 (NF-1) or tuberin (TSC). In particular, the chromosome arm 16p, which 
contains TSC-2, has been found to be lost in 37% of pancreatic NETs [25]. The 
phosphatase and tensin homologue (PTEN) has been also detected mutated or deleted in 
the 10% up to 29% of patients with pancreatic NETs [25]. All these tumor suppressor 
genes, if inactivated, led to an over-expression of the mTOR pathway [26]. Moreover, 
mTOR pathway is linked to a progression of disease, in this context, Missiaglia et al 
showed that the down-regulation of the tumor suppressor of the Akt/mTOR pathway TSC-
2 and PTEN which leads to deregulation of the mTOR pathway are linked to progression 
of pancreatic NETs to an increased rate of proliferation, and shortened PFS and OS [25]. 
Although the crucial role of mTOR seems to be mainly confined in the subgroup of 
pancreatic NETs (in fact about the 14% of these last present mutations in genes in the 
mTOR pathway) [26,27]. The positive recent data from the RADIANT-4 trial [12] based on 
the use of mTOR targeting agent (everolimus) supported the leading role of mTOR axis in 
NETs not only in is pancreatic but also in lung or gastrointestinal tumors.   
The angiogenesis process along with one of its “driver” such as the vascular endothelial 
growth factor (VEGF) play also an important role in NETs progression. Over expression of 
VEGF has been demonstrated in pancreatic or not pancreatic NETs and it has been 
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associated to a worse outcome [26,28]. Moreover the VEGF receptor-2 (VEGFR-2) is also 
generally over-expressed also in gastro-intestinal carcinoid tumors and carcinoid cancers 
[26,29]. Thus, targeting these markers potentially arrest the NETs related-angiogenesis 
inducing, as a consequence, a tumor downstage and an improvement in PFS/OS 
[12,20,21].  
The present study is a systematic review and a meta-analysis of trials to assess the 
efficacy of targeted agents in patients with advanced NET. NETs are a heterogeneous 
disease arising from various primary sites such as the small intestine or other sites of the 
gastrointestinal tract, and the lung [30,31], therefore their management is complicated by a 
different clinical presentations, clinical disease course, symptoms and degree of 
aggressiveness [3]. In our analysis, target agents improved the PFS and OS of advanced 
NETs patients compared with control group. Therefore, we may confirm the important role 
of targeted agents in treating the advanced NETs and in this setting, the completion of 
several randomized phase III studies has brought to the approval of two new sunitinib, and 
everolimus [32]. Because of the observed long survival after progression of many patients, 
PFS is recommended as a feasible and relevant primary end point for both phase III 
studies and phase II studies [33], however we have been able to show a statistically 
significant improvement also in OS for patients with NETs treated with targeted therapies. 
In the subgroup analysis, we have reported a better PFS in patients with pancreatic NETs 
versus other site of NETs (HR=0.49 and 0.71 respectively). However, it is well known for 
chemotherapy and targeted treatment than better response is observed for pancreatic 
NETs than non-pancreatic NETs. Therefore our study empowered this issue. 
The identification of the patients who will benefit or will be resistant to targeted agents is 
mandatory in a clinical setting. Unfortunately, there are less established biomarkers able to 
predict the response of advanced NETs to targeted agents. In the near future, studies 
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based on identification of biomarkers predicting response and clinical benefit to novel 
targeted agents in advanced NETs patients are needed. 
It is worth of notes our meta-analysis presents several important limitations: 1) not all 
considered studies reported data on HRs of OS, PFS and RR, 2) different drugs with 
different mechanism of action have been analysed with different impact on outcome-
related variables, 3) only one study directly compared the combination of two targeted 
therapies, however an increase in toxicity in  the combination arm was observed [21], 4) 
this is not a meta-analysis performed from individual data from randomized studies, but 
from data available in literature, which is known to be much less robust, 5) data on 
toxicities were very heterogeneous and did not allow a reasonable pooling of the results, 
6) although, we found a good global quality of examined studies (median Jadad score of 
5), the quality and the design of clinical studies for advanced NETs are poor [34] due to 
several factors: the heterogeneity of the disease (different primary sites), very low 
incidence leading to a relative paucity of comparative and strategy studies. NET treatment 
strategy may include several options such as surgery, through liver-targeted therapies and 
several lines of systemic therapy.  
Conclusions 
NETs are a heterogeneous disease leading to a very difficult trial design and algorithm of 
therapy. Therefore, the optimal management of advanced NETs is still a challenge for 
medical oncologist. The recent success of phase III trials demonstrate that the novel 
agents such as sunitinib, and everolimus are an effective therapeutic options for patients 
with advanced NETs with particular regards to the pancreatic tumors. While, the 
combination of everolimus plus octreotide LAR improves PFS in patients with advanced 
NETs, no data are available on the antitumor activity of the combination of sunitinib and 
everolimus or sunitinb octreotide and LAR. Nowadays, new pathways with new targeted 
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therapies are under investigation in advanced NETs, but it is still mandatory to design and 
conduct trials properly to solve the issue of the optimal management in any subgroups of 
advanced NETs, maybe thankful also the identification of “driver” biomarker for selected 
treatment.  
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Table 1. Characteristics of the analysed trials. 
Study Design Primary 
endpoint 
Number of 
Patients 
Experimental 
Arm 
Number of 
Patients 
Control Arm 
 Experimental 
drug 
 Control  Tumor 
location 
 Jaded 
score 
Yao 2011 
[10] 
III PFS 207 203 Everolimus Placebo Pancreatic 5 
Raymond 
[11] 
III PFS 86 85 Sunitinib Placebo Pancreatic  5 
Yao 2015 
[12] 
III PFS 205 97 Everolimus Placebo Non-
pancreatic 
NETS 
5 
Pavel 
[18] 
 III  PFS  216  213 Everolimus+ 
Octreotide LAR 
Placebo + 
octreotide 
LAR 
Non-
pancreatic 
NETS 
5 
Yao 2015 
ASCO 
[19] 
III PFS 201 201 Bevacizumab+ 
Octereotide 
Interferon α-
2B+ 
Octereotide 
Non-
pancreatic 
NETS 
4 
 Yao 
2008 [20] 
 II  PFS  22  22  Bevacizumab PEG 
interferon α-
2B 
Non-
pancreatic 
NETS 
3 
Kulke 
2015 [21] 
II 75 75 75 Everolimus+ 
Bevacizumab 
Everolimus Pancreatic 3 
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Table 2. Data on overall survival, progression free survival, median treatment duration and 
median follow-up of the included studies. 
OS: overall survival; PFS: progression free survival; NR: not reported. 
*according to central assessment; ** Weeks; *** Cycles 
  
Study OS (months) P value PFS (months) P value Median 
treatment 
Duration 
(months) 
Median 
Follow-
up 
(months) 
Experimental 
drug 
Control Experimental 
drug 
Control Exp Control 
Yao 2011 [10] NR NR 0.59 11.4* 5.4* < 0.001 8.79 3.74 17 
Raymond [11] NR NR 0.02 11.4 5.5 <0.001 4.6 3.7 NR 
Yao 2015 [12] NR NR 0.04 11 3.9 < 0.0001  40.4** 19.6** 21 
Pavel [18] NR NR NR 16.4 11.3  0.026 9.25 9.15 28 
Yao 2015 
ASCO [19] 
NR NR NR 16.6* 15.4* 0.55 NR NR NR 
Yao 2008 [20] NR NR NR 16.5 14 0.34 4.5 4.5 4.5 
Kulke 2015 [21] 36.7 35 0.16 16.7 14 0.12 13*** 12*** 25.9 
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Figure 1. Trial selection flow chart. 
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Figure 2. Forest plots of hazard ratios (HRs) for overall survival (OS) comparing new target agents to control 
group. The Chi-squared test showed low heterogeneity between the trials. The fixed effects model was used. 
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Figure 3. Forest plots of hazard ratios (HRs) for progression-free survival (PFS) comparing new target 
agents to control group. The Chi-squared test showed high heterogeneity between the trials. The random 
effects model was used 
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Figure 4. Forest plots of hazard ratios (HRs) for progression-free survival (PFS) comparing new target 
agents to control group in the subgroup of pancreatic NETs versus non pancreatic NETs. The Chi-squared 
test showed high heterogeneity between the trials. The random effects model was used 
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